AILERON THERAPEUTICS INC 4
4 · AILERON THERAPEUTICS INC · Filed Jul 6, 2017
Insider Transaction Report
Form 4
Gallagher Brian M. Jr.
Director
Transactions
- Purchase
Common Stock
2017-07-05$15.00/sh+273,333$4,099,995→ 1,431,519 total(indirect: See Footnote) - Conversion
Common Stock
2017-07-05+1,158,186→ 1,158,186 total(indirect: See Footnote) - Conversion
Series D Preferred Stock
2017-07-05−6,781,770→ 0 total(indirect: See Footnote)→ Common Stock (682,476 underlying) - Conversion
Series E-2 Preferred Stock
2017-07-05−1,471,551→ 0 total(indirect: See Footnote)→ Common Stock (148,088 underlying) - Conversion
Series F Preferred Stock
2017-07-05−1,979,188→ 0 total(indirect: See Footnote)→ Common Stock (199,173 underlying) - Conversion
Series E-3 Preferred Stock
2017-07-05−1,276,389→ 0 total(indirect: See Footnote)→ Common Stock (128,448 underlying)
Footnotes (2)
- [F1]The Series D, Series E-2, Series E-3 and Series F Preferred converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]S.R. One, Limited, an indirect wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares. Dr. Brian M. Gallagher, Jr. is a partner and Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect wholly-owned subsidiary of GlaxoSmithKline plc. Dr. Gallagher disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.